Search
forLearn
5 / 801 resultslearn histidine
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn LHA™
learn Biotinyl-GHK
Research
5 / 557 resultsresearch Effects of Solventson Spherical Crystals of Minoxidil
Different solvents affect minoxidil crystal shapes, improving flowability and revealing a unique butterfly-shaped crystal.
research Effects of Solvents on Spherical Crystals of Minoxidil
Different solvents change minoxidil crystal shapes and improve flowability.
research Risk:benefit ratio in the treatment of psoriasis with systemic retinoids
Systemic retinoids are effective for psoriasis but have side effects; benefits may outweigh risks, especially when reducing cancer risks from other treatments.
research Single‐cell transcriptomics reveals a senescence‐associated IL ‐6/ CCR6 axis driving radiodermatitis
Blocking certain immune signals can reduce skin damage from radiation therapy.
research Diagnosis dan Tata Laksana Graves’ Disease
Graves' disease is a common cause of hyperthyroidism, mainly in women, treated with medication, iodine, or surgery, with varying outcomes.
Community Join
5 / 1000+ resultscommunity Hope Medicine HMI-115 Phase 1 Success in Australia! 14 hairs/cm2 increase in hair growth.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
community HMI 115 Phase 2 - Leaked pics from Discord
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HMI-115 start AGA phase 2 trial volunteer in China. The eligible volunteer should be age between 18 to 65, Norwood 3 vertex , 4 and 5. And agree to prevent pregnancy. The trial is leaded by the doctor in Beijing hospital.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.